Clin Lung Cancer: Atezolizumab is effective in treating patients with extensive stage small cell lung cancer in Japan and is well-to-do.

Atezolizumab is effective in treating broad-stage small cell lung cancer (ES-SCLC) and has good patient tolerance, but there are differences in response to systemic therapy in Asian and Caucasian patients.
this study, we evaluated the efficacy and tolerance of Japanese patients in the IMpower133 trial (NCT02763579), which was published online in Clin Lung Cancer.
The main eligibility criteria for this multi-center, double-blind, placebo-controlled, randomized study were: age ≥18 years old; histologically or cytologically proven ES-SCLC, measurable by solid tumor response evaluation standard 1.1; eastern cooperative oncology group with a performance status of 0/1; and no previous systematic treatment of ES-SCLC.
patients were treated with aceticojutin monoantigen 1200 mg or placebo with carabin (5 mg/mL/min under curve) and etoposide (100 mg/m2).
endpoints of the study were the total survival of the intended treatment population and the progress-free survival assessed by the researchers.
42 of the 403 patients randomly admitted to the IMpower133 trial were admitted to the Japanese center.
results, the median total survival of patients in the atezolizumab group (n s 20) was longer than in the placebo group (n s 22; 14.6 months; 8-17.8 months vs.11.9 months; 95% CI, 8.4-15.8; HR, 0.72; 95% CI, 0.31-1.67).
the medium non-progressed lifetimes were 4.5 months (95% CI, 4.2-8.1 months) and 4.0 months (95% CI, 2.9-5.6 months; HR, 0.47; 95% CI, 0.23-0.96).
overall resistance to azizoju monoantigen was good, and no treatment-related deaths occurred.
, the results show that the addition of acetyl monoantigen on the basis of carbaptonin and etoposide can effectively treat ES-SCLC, and the patient's tolerance is good.
results are consistent with the main analysis of the IMpower133 test.
.